DK1685150T3 - Hidtil ukendte 17beta-hydroxysteroiddehydrogenase type I-inhibitorer - Google Patents

Hidtil ukendte 17beta-hydroxysteroiddehydrogenase type I-inhibitorer

Info

Publication number
DK1685150T3
DK1685150T3 DK04804529T DK04804529T DK1685150T3 DK 1685150 T3 DK1685150 T3 DK 1685150T3 DK 04804529 T DK04804529 T DK 04804529T DK 04804529 T DK04804529 T DK 04804529T DK 1685150 T3 DK1685150 T3 DK 1685150T3
Authority
DK
Denmark
Prior art keywords
17beta
inhibitors
new
hydroxysteroid dehydrogenase
dehydrogenase type
Prior art date
Application number
DK04804529T
Other languages
English (en)
Inventor
Josef Messinger
Heinrich-Hubert Thole
Bettina Husen
Steen Bartholomeus Johannes Van
Gyula Schneider
Johannes Bernardus Everardus Hulshof
Pasi Koskimies
Nina Johansson
Jerzy Adamski
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Application granted granted Critical
Publication of DK1685150T3 publication Critical patent/DK1685150T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051Estrane derivatives
    • C07J1/0059Estrane derivatives substituted in position 17 by a keto group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04804529T 2003-11-12 2004-11-11 Hidtil ukendte 17beta-hydroxysteroiddehydrogenase type I-inhibitorer DK1685150T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03104169 2003-11-12
EP04105313 2004-10-26
PCT/EP2004/052925 WO2005047303A2 (en) 2003-11-12 2004-11-11 NOVEL 17β HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS

Publications (1)

Publication Number Publication Date
DK1685150T3 true DK1685150T3 (da) 2008-12-01

Family

ID=34593637

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04804529T DK1685150T3 (da) 2003-11-12 2004-11-11 Hidtil ukendte 17beta-hydroxysteroiddehydrogenase type I-inhibitorer

Country Status (22)

Country Link
EP (1) EP1685150B1 (da)
JP (1) JP4778438B2 (da)
KR (1) KR101070025B1 (da)
AR (1) AR046580A1 (da)
AT (1) ATE407139T1 (da)
AU (1) AU2004289459B2 (da)
BR (1) BRPI0416551A (da)
CA (1) CA2545704C (da)
DE (1) DE602004016373D1 (da)
DK (1) DK1685150T3 (da)
ES (1) ES2314478T3 (da)
HK (1) HK1099309A1 (da)
HR (1) HRP20080603T3 (da)
IL (1) IL175220A (da)
NO (1) NO20062679L (da)
PL (1) PL1685150T3 (da)
PT (1) PT1685150E (da)
RU (1) RU2369614C2 (da)
SA (1) SA04250373B1 (da)
SI (1) SI1685150T1 (da)
TW (1) TWI331154B (da)
WO (1) WO2005047303A2 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
US8030298B2 (en) 2005-05-26 2011-10-04 Abbott Products Gmbh 17β-HSD1 and STS inhibitors
CN101189251B (zh) * 2005-05-26 2012-09-12 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
CA2643670A1 (en) * 2006-02-27 2007-08-30 Sterix Limited Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
JP5268917B2 (ja) * 2006-09-19 2013-08-21 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療学的に有効なトリアゾール類及びそれらの使用
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
CN101568547B (zh) * 2006-11-30 2014-06-25 索尔瓦药物有限公司 作为17βHSD抑制剂的被取代的雌三烯衍生物
DE102007015169A1 (de) * 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
DE102007040243A1 (de) 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
NZ707955A (en) 2010-09-23 2016-03-31 Abbvie Bahamas Ltd Monohydrate of an azaadamantane derivative
US11072632B2 (en) 2011-03-25 2021-07-27 UNIVERSITé LAVAL Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10
JP6456373B2 (ja) 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド 17β−ヒドロキシステロイドデヒドロゲナーゼ タイプ1の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
EP3013845B1 (en) 2013-06-25 2020-03-18 Forendo Pharma Ltd Therapeutically active estratrienthiazole derivatives as inhibitors of 17b-hydroxysteroid dehydrogenase, type 1
EA201690077A1 (ru) 2013-06-25 2016-09-30 Форендо Фарма Лтд. Терапевтически активные производные эстратриен-тиазола
US10413557B2 (en) 2014-12-23 2019-09-17 Forendo Pharma Ltd. Prodrugs of 17.BETA.-HSD1-inhibitors
JP6545266B2 (ja) * 2014-12-23 2019-07-17 フォレンド ファーマ リミテッド 17β‐HSD1抑制剤のプロドラッグ
CZ307437B6 (cs) 2016-06-07 2018-08-22 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz
IL294140B2 (en) * 2017-06-08 2024-09-01 Forendo Pharma Ltd 15beta-(3-propanamido)-converted ester-1, 3, 5(10)-triane-17-oximes used in the inhibition of 17beta-hydroxysteroid dehydrogenases
BR112021010598A2 (pt) * 2018-12-05 2021-08-24 Forendo Pharma Ltd Compostos, método para preparação de um composto e composição farmacêutica

Also Published As

Publication number Publication date
PT1685150E (pt) 2008-11-12
BRPI0416551A (pt) 2007-02-27
IL175220A0 (en) 2006-09-05
IL175220A (en) 2010-12-30
WO2005047303A2 (en) 2005-05-26
SI1685150T1 (sl) 2008-12-31
RU2369614C2 (ru) 2009-10-10
CA2545704C (en) 2012-06-26
TWI331154B (en) 2010-10-01
AU2004289459B2 (en) 2010-08-19
CA2545704A1 (en) 2005-05-26
EP1685150B1 (en) 2008-09-03
WO2005047303A3 (en) 2005-08-25
DE602004016373D1 (de) 2008-10-16
KR101070025B1 (ko) 2011-10-04
TW200521133A (en) 2005-07-01
ES2314478T3 (es) 2009-03-16
HRP20080603T3 (en) 2009-03-31
SA04250373A (ar) 2005-12-03
PL1685150T3 (pl) 2009-02-27
ATE407139T1 (de) 2008-09-15
RU2006120488A (ru) 2008-01-10
AR046580A1 (es) 2005-12-14
AU2004289459A1 (en) 2005-05-26
JP4778438B2 (ja) 2011-09-21
EP1685150A2 (en) 2006-08-02
NO20062679L (no) 2006-08-10
HK1099309A1 (en) 2007-08-10
KR20060121171A (ko) 2006-11-28
JP2007510697A (ja) 2007-04-26
SA04250373B1 (ar) 2009-12-22

Similar Documents

Publication Publication Date Title
DK1685150T3 (da) Hidtil ukendte 17beta-hydroxysteroiddehydrogenase type I-inhibitorer
DE602004018837D1 (de) Ptidase-iv-inhibitoren
ATE446090T1 (de) Thiadiazolidinone als gsk3-inhibitoren
DK2253614T3 (da) IAP-inhibitorer
DK1778718T3 (da) Iap-inhibitorer
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
ATE423121T1 (de) Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
ATE545642T1 (de) Mmp-inhibitoren
DK1534290T3 (da) Hidtil ukendte kinasehæmmere
ATE401893T1 (de) Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitoren
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20076678L (no) Glutamataggrekanaseinhibitorer
ATE462692T1 (de) 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer
DE602005008726D1 (de) Verwendet
DK1692242T3 (da) Viskoelastisk syre
DE60324208D1 (de) Biarylsulfonamide als mmp-inhibitoren
ATE396724T1 (de) 1h-thieno 2,3-c-pyrazol-derivate als kinase-i- hemmer
DK1713805T3 (da) Kinaseinhibitorer
ATE401914T1 (de) Kassettenanordnung
ATE373648T1 (de) Nf-kappab-inhibitoren
ITMI20041626A1 (it) Inibitori della chinurenina-ammino-trasferasi
DE60328233D1 (de) Sulfamatbenzothiophenderivate als steroidsulfataseinhibitoren